According to the National Cancer Institute (NCI) triple negative breast cancer is subtype of breast

1100 WordsApr 23, 20195 Pages
According to the National Cancer Institute (NCI) triple negative breast cancer is subtype of breast cancer that lack estrogen receptors, progesterone receptors or large amounts of HER2/neu proteins. It’s commonly known as ER-negative, PR-negative and HER2/neu-negative breast cancer (1). Due to the aforementioned characteristic of triple negative breast cancer it is insensitive to most of the effective therapies available for breast cancer treatment including HER2-directed therapy such as trastuzumab (2). Chemotherapy is the only systemic treatment for Triple Negative Breast Cancer. Even though standard chemotherapy regimens can be effective for patients in the early stages of triple negative breast cancer, but patients with…show more content…
Second generation Antibody-drug conjugate consider as a new approach for treatments of TNBC. The main idea is to use an antibody and cytotoxic agents together to produce a synergistic effect and to ensure delivery of the cytotoxic agent to the target cell (6) Our main goal in this research is to develop a novel antibody based therapy against LRP8. We hypothesis that an anti-LRP8 antibody conjugated to cytotoxic drug will lead toward effective therapy for TNBC. We will perform experiments using flow cytometry and confocal microscopy to prove that LRP8 is suitable ADC target. Two main factors will contribute to whether it is suitable target: i. 100,000 LPR8 receptors should be expressed on the surface of 18-20 cells line. Our hypothesis is that will be more than 100,000 LPR8 receptors on the surface of breast cancer cell line. ii. Internalization of antibody bound to LRP8 We hypothesis that the antibody bind to the LRP8 have the ability to internalize and eventually causes cell death or apoptosis. Background and Preliminary Results: In February 2013, an anti-HER2 antibody trastuzumab was approved by the FDA following the positive outcome of the Phase III EMILIA trial. In this trial, Patients with HER2 (also known as ERBB2)-positive metastatic breast cancer had an improved median overall survival benefit compared to the combination of lapatinib and capecitabine (6). This drug represents an

More about According to the National Cancer Institute (NCI) triple negative breast cancer is subtype of breast

Open Document